Levels of 8-oxo-7,8-dihydro-2′-deoxyguanosine and ceramide are increased in CGSPGWVRC-GG-D(KLAKLAK)2-treated lungs (21 days of treatment). a, CGSPGWVRC-GG-D(KLAKLAK)2 peptide induces oxidative damage to mouse lungs, as indicated by increasing 8-oxo-dG expression. Immunohistochemical staining of 8-oxo-dG in lung sections from mice treated for 21 days with CGSPGWVRC-GG-D(KLAKLAK)2 peptide, control peptides (CGSPGWVRC and D(KLAKLAK)2), or vehicle alone. Isotype control antibody on CGSPGWVRC-GG-D(KLAKLAK)2 peptide-treated lungs served as a negative control for anti-8-oxo-dG staining. Lung sections from the CGSPGWVRC-GG-D(KLAKLAK)2-treated mice show elevated 8-oxo-dG expression compared with control-treated mice. Scale bar (a and c), 25 μm. b, quantification of the 8-oxo-dG intensity in the lung tissues from CGSPGWVRC-GG-D(KLAKLAK)2-treated mice. c and d, analysis of ceramide species by mass spectrometry shows that lungs of mice treated with the CGSPGWVRC-GG-D(KLAKLAK)2 peptide for 7 days have increased levels of ceramides (c) as well as dihydroceramides, ceramide precursors in the de novo pathway of ceramide synthesis (d), compared with the lungs from control peptide (CGSPGWVRC or D(KLAKLAK)2)-treated mice. e, CGSPGWVRC-GG-D(KLAKLAK)2 peptide induces elevation of ceramide levels in mouse lungs. Lung sections from mice after 21 days of treatment with CGSPGWVRC-GG-D(KLAKLAK)2 peptide, control peptides (CGSPGWVRC and D(KLAKLAK)2), or vehicle alone were subjected to immunohistochemical staining for ceramide. Ceramide staining in CGSPGWVRC-GG-D(KLAKLAK)2 peptide-treated lungs show numerous ceramide-positive alveolar cells, whereas lungs treated with control peptides or vehicle show only sporadic ceramide-positive cells. f, quantification of ceramide expression detected by immunohistochemistry is described under “Materials and Methods.”